经皮冠状动脉介入治疗术后阿司匹林应用剂量的研究进展

自冠状动脉支架应用于临床以来,经皮冠状动脉介入治疗后阿司匹林的剂量一直是人们争论的问题.国外多项大规模的临床研究表明：经皮冠状动脉介入治疗后服用小剂量阿司匹林（75-100 mg/d）、较大剂量阿司匹林（≥300 mg/d）并不增加不良心血管事件,而且明显减少出血并发症.我们对中国人经皮冠状动脉介入治疗术后阿司匹林不同剂量的有效性和安全性研究较少,有待国内展开大规模的临床试验,为临床合理用药提供循证依据.

Current Research in Dose of Aspirin after Percutaneous Coronary Intervention

The optimal dose of aspirin after percutaneous coronary intervention（PCI） has been debated since the clinical application of coronary stent. A number of large-scale clinical studies abroad shows that low-dose aspirin （75 - 100 mg/d） does not increase major adverse cardiovascular events, but can reduce the bleeding complication after PCI compared with high-dose aspirin （ ≥300 mg/d）. There are seldom researches about the efficacy and safety of different doses of aspirin after PCI in our country. It is still unclear whether low-dose aspirin is more appropriate for Chinese patients undergoing PCI than high-dose aspirin. We are looking forward to domestic large-scale clinical trials on this issue.